key: cord-0898846-w1tyq1jl
authors: El Rhalete, Abdelilah; Rhazi, Inas; Bensaid, Amine; Zaid, Ikram; Bkiyer, Houssam; Ismaili, Nabila; Elouafi, Nouha; Housni, Brahim
title: Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
date: 2021-04-18
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102309
sha: e101948b825709b0edffc020c8f27a8d142272e9
doc_id: 898846
cord_uid: w1tyq1jl

BACKGROUND: To date, more than 105,805,951 cases of COVID-19 have been diagnosed including 2,312,278 deaths. Many patients have cardiovascular risk-factors and/or co-morbidities and a lot of them developed de novo heart conditions during the active or the post-infectious phase of the infection. A number of studies tried to demonstrate an association between poor prognostic outcomes and cardiovascular comorbidities and related damages, but the quality of current evidence is still weak. PATIENTS AND METHODS: The aim of this single-center report is to describe the prevalence of cardiac injuries among our COVID-19 patients, to explore their association with survival outcomes and to demonstrate the medical care provided in our real-world setting. Our study included 610 COVID-19 patients admitted to the intensive care unit of our university hospital of whom13.77% (n = 84) presented cardiovascular injuries and which we included in this case series. RESULTS: The average age of our patients was 65 years (27–90). 60 were men (71.42%) while 24 were women (28.55%). Their average BMI was 29.7 kg/m(2). Among them, 50 had a pulmonary embolism (59.52%), 12 patients had a myocardial infarction (14.28%), 10 presented pericarditis (11.9%) and 3 developed myocarditis (3.57%). There were 6 cases of ischemia (7.14%), 2 cases of stroke (2.38%), and 1 case of decompensated heart failure (1.19%). Among our patients, 46.42% had diabetes, 32.14% had a high blood pressure, 13.09% had a chronic renal failure and 14.28% had a history of ischemic heart disease. 14 patients (16.66%) had an elevated troponin with higher levels than 1000 ng/mL. The D-dimer value was high in almost all patients (80.95%). Lung damage from COVID-19 was extensive in 27.38%, severe in 32.14%, and critical in 40.47% of enrolled cases. CT chest angiography, ECG, and cardiac ultrasound were performed to the paraclinical confirmatory exploration of cardiac damages of these patients. Medical care was based on isolation, azithromycin, vitamin C, zinc, vitamin D, salicylic acid, dexamethasone followed with methylprednisolone, and anticoagulation for all hospitalized patients. Tocilizumab was indicated for 17 patients with hyperferritinemia (20.23% of patients). The initial respiratory care of our patients required oxygen therapy using nasal cannula (7.14%) high concentration masks (33.33%), high flow nasal cannula treatment (11.9%), non-invasive ventilation (NIV) (5.95%), and mechanical ventilation (41.66%). Thrombolysis was performed in three subjects with myocardial infarction and 2 underwent angioplasty with placement of an active stent at the proximal interventricular anterior artery, which all were successful. Three massive pulmonary embolisms died despite adequate treatment. Colchicine and salicylic acid were administered for pericarditis cases. Thromboprophylaxis was indicated for all patients and was reinforced if a venous thrombotic episode was confirmed. Patients with limb ischemia underwent surgical treatment. Among the 84 patients included in our cohort, 34 (40.47%) died in intensive care unit and 50 (59.52%) had a favorable evolution. CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.

(71.42%) while 24 were women (28.55%). Their average BMI was 29.7 kg/m 2 . 23 Among them, 50 had a pulmonary embolism (59.52%), 12 patients had a myocardial 24 infarction (14.28%), 10 presented pericarditis (11.9%) and 3 developed myocarditis 25

(3.57%). There were 6 cases of ischemia (7.14%), 2 cases of stroke (2.38%), and 1 26 case of decompensated heart failure (1.19%). Among our patients, 46.42% had 27 diabetes, 32.14% had a high blood pressure, 13.09% had a chronic renal failure and 28 14.28% had a history of ischemic heart disease. 14 patients (16.66%) had an 29 elevated troponin with higher levels than 1000 ng/mL. The D-dimer value was high in CoV-2, the viral agent responsible for the COVID-19 infection is a single-stranded 87 RNA virus that invades body cells through the ACE-2 receptor [9] . The entry of the 88 pathogen into human cells is facilitated by the interaction of a viral tip protein with this 89 receptor. ACE-2 is a membrane-bound mono-carboxy-peptidase, expressed mainly 90 on the surface of lung, kidney, intestinal and heart cells. Thus, a more severe form of 91 the infection in patients with cardiovascular disease could be due to increased 92 secretion of ACE-2 in these patients as compared to healthy individuals [10] . 93

Patients with comorbidities like heart conditions are therefore not only at high risk of 94 becoming infected but also at risk of a more severe and fatal infection [11, 12] 

Among these patients, 50 had a pulmonary embolism (59.52%); three of them were 133 massive. Twelve patients had a myocardial infarction (14.28%), ten presented 134 pericarditis (11.9%) and three developed myocarditis (3.57%). In addition, six cases 135 presented an ischemia (7.14%) including two patients with Leriche syndrome 136 J o u r n a l P r e -p r o o f (associated with segmental pulmonary embolism in one case), three patients with 137 ischemia of the lower limb, and only 1 case of ischemia of the upper limb. Besides, 138 there were 2 cases of ischemic stroke (2.38%) and 1 case of decompensated heart 139 failure (1.19%).The distribution of cardiovascular injuries is shown in Figure 2 . 140 141

In our study, 9 patients had a history of active smoking. 46.42% had diabetes, 143 32.14% had a high blood pressure, 13.09% had a chronic renal failure and 14.28% 144 had a history of ischemic heart disease; of them, 3 patients had active stent, 1 with a 145 coronary artery bypass graft surgery, and the rest with medical treatment only. Table  146 1 summarizes the detailed description of medical history of our case series. The most 147 common symptoms were dyspnea, fever, asthenia, cough, chest pain and diarrhea. 148

Headache, myalgia, anosmia and ageusia were also common signs in our patients 149 (Table 1) Table  163 1. 164 165

In this series, 14 patients (16.66%) had elevated troponin levels (> 1000 ng/mL). suggested mechanism is the imbalance between the myocardial oxygen needs and 272 supplies. Indeed, the severe hypoxia that exists during acute lung injury due to 273 forms of myocarditis with acute impairment of LV function. The diagnosis of 292 myocarditis is not easy in this context. The most typical ECG aspect of myocarditis is 293 usually the appearance of non-specific T wave changes as might be seen in ACS or 294 left ventricular hypertrophy. In myocarditis, very high troponin levels (> 10,000ng / L), 295 signify a sometimes-fulminant cardiac involvement. Regarding the prognosis, a few 296 deaths of COVID-19 patients linked to this myocarditis are reported, but this 297 incidence seems low. Fortunately, it's also the case in our study with only one 298 myocarditis death. 299

Significant differences between the initial troponinemia levels were observed 300 between the cured and the deceased myocarditis patients [34] . Normalizations of 301 hemodynamic parameters, oxygenation and cardiac function have been reported 302 during the administration of treatments modulating inflammation such as 303 J o u r n a l P r e -p r o o f methylprednisolone or immunoglobulins [35] , as was the case for us. Coagulation 304 abnormalities and arrhythmias are also common in patients with COVID-19, although 305 the mechanism is still poorly understood [36, 37] . Rhythm disturbances have been 306 suspicion of pulmonary embolism [26] , which was the case of one patient in our 333 series. The age greater than or equal to 75 years, the existence of a history of 334 venous thromboembolism, obesity, active cancer, cardiac or respiratory insufficiency 335 are also risk factors for DVT that add to the inherent risk of viral infection. In our 336 J o u r n a l P r e -p r o o f series, obesity was a major risk factor of thrombo-embolic lesions. Inflammation is 337 often marked in COVID-19 infection, especially in severe forms, leading to 338 sometimes considerable elevations of D-dimers (> 10,000μg/L), fibrinogen (> 8g/L) 339 and CRP (> 100mg/L), which is in line with our findings. 340

According to another report that enrolled 1099 patients, hypertension was present in 342 almost 15%, diabetes in around 7%, coronary heart disease in only 2.5% [43] . 343 However, our data indicate a higher rate with 46.42% of diabetes, 32.14% of 344 hypertension and 14.28% ischemic heart disease. This difference might be due to the 345 large sample used for that report (severe and non-severe patients) meanwhile our 346 study had just critical COVID-19 patients. Thus, they had more comorbidities. As 

The 615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649 654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684 

SARS-CoV-2 406 and limb ischemia: A systematic review

Quantifying and reporting 410 cardiac findings in imaging of COVID-19 patients. Monaldi Arch Chest Dis

Cardiovascular disease and COVID-19

Prevalence of comorbidities in the Middle East respiratory 416 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Clinical features of patients infected with 2019 novel 421 coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients 423 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting 427 OfCasESeries in Surgery (PROCESS) Guidelines

Association of Cardiac Injury With Mortality in 431 Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol

The cardiovascular burden of coronavirus disease 2019 435 (COVID-19) with a focus on congenital heart disease

Circulation

Renin-angiotensin system at the heart 444 of COVID-19 pandemic

SARS-CoV-2 and 448 cardiovascular complications: From molecular mechanisms to pharmaceutical 449 management

SARS-coronavirus modulation of myocardial 452 ACE2 expression and inflammation in patients with SARS

Genomic characterisation and epidemiology of 2019 455 novel coronavirus: implications for virus origins and receptor binding

An Acute Respiratory Infection Runs Into the Most Common 459 Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA 460 Cardiol

Pathogenic human coronavirus infections: 463 causes and consequences of cytokine storm and immunopathology. Semin 464 Immunopathol

Association of Coronavirus 470 Disease 2019 (COVID-19) With Myocardial Injury and Mortality

Potential Effects of 473 Coronaviruses on the Cardiovascular System: A Review

COVID-19 and the cardiovascular 475 system

A Novel Coronavirus 477 from Patients with Pneumonia in China

Cardiovascular Implications 480 of Fatal Outcomes of Patients With Coronavirus Disease

Acute myocardial 483 injury is common in patients with covid-19 and impairs their prognosis

Clinical course and risk factors for 486 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 487 study

Cardiovascular considerations for patients, health care workers, and health systems 490 during the COVID-19 pandemic

Prevalence and impact of cardiovascular metabolic 492 diseases on COVID-19 in China

Coronaviruses and the 494 cardiovascular system: acute and long-term implications

an Clinical course and outcomes of 497 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-498 centered, retrospective, observational study

Coronavirus fulminant 500 myocarditis treated with glucocorticoid and human immunoglobulin 501

Coagulation abnormalities and thrombosis in 502 patients with COVID-19

Cardiac Arrhythmias in COVID-19 Infection. Circulation Arrhythmia and 505 electrophysiology

Clinical characteristics 507 of novel coronavirus cases in tertiary hospitals in Hubei Province

Incidence of thrombotic complications in critically ill ICU patients with 511 COVID-19

 Figure 1  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611 Patient with abnormally elevated cardiac enzymes (troponin, CPK), D-dimer, electrical signs on the electrocardiogram and / or suggestive echocardiographic signs Hypoxic cardiac arrest before admission, patient with advanced heart failure, or agonizing Patients over 15 years, admitted to intensive care from March 1 st 2020 to December 31 st 2020, who had de novo ventricular cardiac dysfunction; in the acute phase of a COVID-19 infection with positive RT-PCR or in the postinfectious phase with positive serology

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. This is a retrospective case series that does not require a formal ethical committee approval. Data were anonymously registered in our database. Access to data was approved by the head of the department J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions,the Editor in Chiefmust be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. 

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Prof. Brahim Housni Dr Abdelilah El Rhalete and Dr Inas Rhazi